abstract：:Vaccination is one of the most successful medical interventions that has saved the life of millions of people. Vaccination is particularly important in patients with multiple myeloma, who have an increased risk of infections due to the disease-inherent immune suppression, and because of the immune suppressive effects ...

journal_title：Leukemia

authors： Ludwig H,Boccadoro M,Moreau P,San-Miguel J,Cavo M,Pawlyn C,Zweegman S,Facon T,Driessen C,Hajek R,Dimopoulos MA,Gay F,Avet-Loiseau H,Terpos E,Zojer N,Mohty M,Mateos MV,Einsele H,Delforge M,Caers J,Weisel K,Jackso

更新日期：2021-01-01 00:00:00

abstract：:This study investigated the relationships between HDL-C and major types of blood cancers. Competing risks regression was used to examine the hazard ratios of hematologic malignancies in 9,596,145 individuals (≥20 years) using data from the Korean National Health Insurance Service (2009-2017). The incidence of the foll...

journal_title：Leukemia

authors： Jeong SM,Choi T,Kim D,Han K,Kim SJ,Rhee SY,Giovannucci EL,Shin DW

更新日期：2020-12-02 00:00:00

abstract：:The fate options of hematopoietic stem cells (HSCs) include self-renewal, differentiation, migration, and apoptosis. HSCs self-renewal divisions in stem cells are required for rapid regeneration during tissue damage and stress, but how precisely intracellular calcium signals are regulated to maintain fate options in n...

journal_title：Leukemia

authors： Grahn THM,Niroula A,Végvári Á,Oburoglu L,Pertesi M,Warsi S,Safi F,Miharada N,Garcia SC,Siva K,Liu Y,Rörby E,Nilsson B,Zubarev RA,Karlsson S

更新日期：2020-12-01 00:00:00

abstract：:Chimeric antigen receptor (CAR) T cell therapies lead to high clinical response rates in B cell malignancies, and are under investigation for treatment of solid tumors. While high systemic interleukin- (IL-) 6 levels are associated with clinical cytokine release syndrome (CRS), the role of IL-6 trans-signaling within ...

journal_title：Leukemia

authors： Jiang Z,Liao R,Lv J,Li S,Zheng D,Qin L,Wu D,Chen S,Long Y,Wu Q,Wang S,Lin S,Huang X,Tang Z,Shi P,Zhou H,Liu Q,Zhao R,Li Y,Jie Y,Wei W,Lai P,Du X,Cui S,Weinkove R,Liu P,Pei D,Yao Y,Li P

更新日期：2020-11-09 00:00:00

abstract：:The hematopoietic system is sustained by a rare population of hematopoietic stem cells (HSCs), which emerge during early embryonic development and then reside in the hypoxic niche of the adult bone marrow microenvironment. Although leptin receptor (Lepr)-expressing stromal cells are well-studied as critical regulators...

journal_title：Leukemia

authors： Trinh T,Ropa J,Aljoufi A,Cooper S,Sinn A,Srour EF,Broxmeyer HE

更新日期：2020-11-07 00:00:00

abstract：:Multiple myeloma (MM) is an incurable plasma cell malignancy characterized by clonal proliferation of plasma cells and a heterogenous genomic landscape. Copy number and structural changes due to chromosomal instability (CIN) are common features of MM. In this review, we describe how primary and secondary genetic event...

journal_title：Leukemia

authors： Neuse CJ,Lomas OC,Schliemann C,Shen YJ,Manier S,Bustoros M,Ghobrial IM

更新日期：2020-11-01 00:00:00

abstract：:An amendment to this paper has been published and can be accessed via a link at the top of the paper. ...

journal_title：Leukemia

authors： Prutsch N,Gurnhofer E,Suske T,Liang HC,Schlederer M,Roos S,Wu LC,Simonitsch-Klupp I,Alvarez-Hernandez A,Kornauth C,Leone DA,Svinka J,Eferl R,Limberger T,Aufinger A,Shirsath N,Wolf P,Hielscher T,Sternberg C,Aberger F

更新日期：2020-11-01 00:00:00

abstract：:Bruton's tyrosine kinase (BTK) inhibitor is a promising novel agent that has potential efficiency in B-cell malignancies. It took approximately 20 years from target discovery to new drug approval. The first-in-class drug ibrutinib creates possibilities for an era of chemotherapy-free management of B-cell malignancies,...

journal_title：Leukemia

authors： Wen T,Wang J,Shi Y,Qian H,Liu P

更新日期：2020-10-29 00:00:00

abstract：:East Asians, Asian Indians and Amerindians have a five to ten-fold lower age-adjusted incidence rate (AAIR) of chronic lymphocytic leukaemia (CLL) compared with persons of predominately European descent. The data we review suggest a genetic rather than environmental basis for this discordance. All these populations ar...

journal_title：Leukemia

authors： Yang S,Varghese AM,Sood N,Chiattone C,Akinola NO,Huang X,Gale RP

更新日期：2020-10-19 00:00:00

abstract：:Chimeric antigen receptor (CAR)-T-cell is a safe and effective therapy of B-cell cancers but it is unknown if this is so in persons with prior hepatitis B virus (HBV) infection. We studied 70 subjects with advanced B-cell cancers receiving CAR-T-cell therapy, 12 of whom had chronic HBV-infection (HBsAg positive) and 2...

journal_title：Leukemia

authors： Wang Y,Liu Y,Tan X,Pan B,Ge J,Qi K,Cheng H,Cao J,Shi M,Yan Z,Qiao J,Jing G,Wang X,Sang W,Xia R,Zhang X,Li Z,Gale RP,Zheng J,Zhu F,Xu K

更新日期：2020-10-01 00:00:00

abstract：:An amendment to this paper has been published and can be accessed via a link at the top of the paper. ...

journal_title：Leukemia

authors： Thastrup M,Marquart HV,Levinsen M,Grell K,Abrahamsson J,Albertsen BK,Frandsen TL,Harila-Saari A,Lähteenmäki PM,Niinimäki R,Pronk CJ,Ulvmoen A,Vaitkevičienė G,Taskinen M,Schmiegelow K,Nordic Society of Pediatric Hematology a

更新日期：2020-10-01 00:00:00

abstract：:We previously reported the benefit of lomustine addition to conventional chemotherapy in older acute myeloid leukemias with nonadverse chromosomal aberrations in the LAM-SA 2007 randomized clinical trial (NCT00590837). A molecular analysis of 52 genes performed in 330 patients included in this trial, 163 patients bein...

journal_title：Leukemia

authors： Largeaud L,Cornillet-Lefebvre P,Hamel JF,Dumas PY,Prade N,Dufrechou S,Plenecassagnes J,Luquet I,Blanchet O,Banos A,Béné MC,Bernard M,Bertoli S,Bonmati C,Fornecker LM,Guièze R,Haddaoui L,Hunault M,Ianotto JC,Jourdan

更新日期：2020-09-18 00:00:00

abstract：:Currently available data on chimeric antigen receptor (CAR)-T cell therapy has demonstrated efficacy and manageable toxicity in heavily pretreated multiple myeloma (MM) patients. The CAR-T field in MM is rapidly evolving with >50 currently ongoing clinical trials across all phases, different CAR-T design, or targets. ...

journal_title：Leukemia

authors： Gagelmann N,Riecken K,Wolschke C,Berger C,Ayuk FA,Fehse B,Kröger N

更新日期：2020-09-01 00:00:00

abstract：:The impact of cancer on outcome of persons with coronavirus disease 2019 (COVID-19) after infection with acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is controversial. We studied 1859 subjects with COVID-19 from seven centers in Wuhan, China, 65 of whom had cancer. We found having cancer was an independent ri...

journal_title：Leukemia

authors： Li Q,Chen L,Li Q,He W,Yu J,Chen L,Cao Y,Chen W,Di Wu,Dong F,Cai L,Ran Q,Li L,Liu Q,Ren W,Gao F,Wang H,Chen Z,Gale RP,Hu Y

更新日期：2020-09-01 00:00:00

abstract：:Data on outcome in older (≥70 years) patients with acute promyelocytic leukemia after treatment with arsenic trioxide (ATO) compared with standard chemotherapy (CTX) is scarce. We evaluated 433 patients (median age, 73.4 years) treated either with ATO+ all-trans retinoic acid (ATO/ATRA; n = 26), CTX/ATRA + ATO during ...

journal_title：Leukemia

authors： Kayser S,Rahmé R,Martínez-Cuadrón D,Ghiaur G,Thomas X,Sobas M,Guerci-Bresler A,Garrido A,Pigneux A,Gil C,Raffoux E,Tormo M,Vey N,de la Serna J,Salamero O,Lengfelder E,Levis MJ,Fenaux P,Sanz MA,Platzbecker U,Schlen

更新日期：2020-09-01 00:00:00

abstract：:An amendment to this paper has been published and can be accessed via a link at the top of the paper. ...

journal_title：Leukemia

authors： Weisberg E,Meng C,Case A,Sattler M,Tiv HL,Gokhale PC,Buhrlage S,Wang J,Gray N,Stone R,Liu S,Bhagwat SV,Tiu RV,Adamia S,Griffin JD

更新日期：2020-09-01 00:00:00

abstract：:We assessed the epidemiologic progress against childhood and adolescent acute lymphoblastic leukaemia (ALL) in the Netherlands over a 26 year period. ALL patients <18 years were selected from the Netherlands Cancer Registry and the Dutch Childhood Oncology Group. Trend analyses were performed over time and by age grou...

journal_title：Leukemia

authors： Reedijk AMJ,Coebergh JWW,de Groot-Kruseman HA,van der Sluis IM,Kremer LC,Karim-Kos HE,Pieters R

更新日期：2020-08-21 00:00:00

abstract：:Histone acetyltransferases (HATs) catalyze the transfer of an acetyl group from acetyl-CoA to lysine residues of histones and play a central role in transcriptional regulation in diverse biological processes. Dysregulation of HAT activity can lead to human diseases including developmental disorders and cancer. Through...

journal_title：Leukemia

authors： Au YZ,Gu M,De Braekeleer E,Gozdecka M,Aspris D,Tarumoto Y,Cooper J,Yu J,Ong SH,Chen X,Tzelepis K,Huntly BJP,Vassiliou G,Yusa K

更新日期：2020-08-06 00:00:00

abstract：:Myeloid neoplasms are characterized by frequent mutations in at least seven components of the spliceosome that have distinct roles in the process of pre-mRNA splicing. Hotspot mutations in SF3B1, SRSF2, U2AF1 and loss of function mutations in ZRSR2 have revealed widely different aberrant splicing signatures with littl...

journal_title：Leukemia

authors： Hershberger CE,Moyer DC,Adema V,Kerr CM,Walter W,Hutter S,Meggendorfer M,Baer C,Kern W,Nadarajah N,Twardziok S,Sekeres MA,Haferlach C,Haferlach T,Maciejewski JP,Padgett RA

更新日期：2020-08-04 00:00:00

abstract：:Early molecular response is associated with improved probability of deep molecular response and superior survival in patients with CML-CP. However, ~1 in 3 patients on first-line imatinib do not achieve this threshold. The phase 2b DASCERN trial (NCT01593254) assessed the outcome of early switch to dasatinib in patien...

journal_title：Leukemia

authors： Cortes JE,Jiang Q,Wang J,Weng J,Zhu H,Liu X,Hochhaus A,Kim DW,Radich J,Savona M,Martin-Regueira P,Sy O,Gurnani R,Saglio G

更新日期：2020-08-01 00:00:00

abstract：:The scientific community faces an unexpected and urgent challenge related to the SARS-CoV-2 pandemic and is investigating the role of receptors involved in entry of this virus into cells as well as pathomechanisms leading to a cytokine "storm," which in many cases ends in severe acute respiratory syndrome, fulminant m...

journal_title：Leukemia

authors： Ratajczak MZ,Kucia M

更新日期：2020-07-01 00:00:00

abstract：:The prognostic value of IL7-receptor pathway (IL7Rp) mutations in T-cell acute lymphoblastic leukemia (T-ALL) remains unclear. We performed a comprehensive study of 200 adult patients with T-ALL included in the GRAALL2003/2005 protocols to address the clinical significance of IL7Rp mutations. Next-generation sequencin...

journal_title：Leukemia

authors： Kim R,Boissel N,Touzart A,Leguay T,Thonier F,Thomas X,Raffoux E,Huguet F,Villarese P,Fourrage C,Passini L,Hunault M,Lepretre S,Chevallier P,Braun T,Lhéritier V,Chantepie S,Maury S,Escoffre M,Tavernier E,Chalandon

更新日期：2020-07-01 00:00:00

abstract：:Current guidelines for smoldering multiple myeloma (SMM) recommend active monitoring until the onset of multiple myeloma (MM) before initiating treatment or enrollment in a clinical trial. Earlier intervention may delay progression to MM. In CENTAURUS, 123 patients with intermediate-risk or high-risk SMM were randomly...

journal_title：Leukemia

authors： Landgren CO,Chari A,Cohen YC,Spencer A,Voorhees P,Estell JA,Sandhu I,Jenner MW,Williams C,Cavo M,van de Donk NWCJ,Beksac M,Moreau P,Goldschmidt H,Kuppens S,Bandekar R,Clemens PL,Neff T,Heuck C,Qi M,Hofmeister CC

更新日期：2020-07-01 00:00:00

abstract：:All-trans-retinoic acid (ATRA) is highly active in acute promyelocytic leukemia but not in other types of acute myeloid leukemia (AML). Previously, we showed that ATRA in combination with Lysine-specific demethylase 1 (LSD1) inhibition by tranylcypromine (TCP) can induce myeloid differentiation in AML blasts. This pha...

journal_title：Leukemia

authors： Wass M,Göllner S,Besenbeck B,Schlenk RF,Mundmann P,Göthert JR,Noppeney R,Schliemann C,Mikesch JH,Lenz G,Dugas M,Wermke M,Röllig C,Bornhäuser M,Serve H,Platzbecker U,Foerster KI,Burhenne J,Haefeli WE,Müller LP,Bind

更新日期：2020-06-19 00:00:00

abstract：:The introduction of BCR-ABL tyrosine kinase inhibitors has revolutionized the treatment of chronic myeloid leukemia (CML). A major clinical aim remains the identification and elimination of low-level disease persistence, termed "minimal residual disease". The phenomenon of disease persistence suggests that despite tar...

journal_title：Leukemia

authors： Kinstrie R,Horne GA,Morrison H,Irvine D,Munje C,Castañeda EG,Moka HA,Dunn K,Cassels JE,Parry N,Clarke CJ,Scott MT,Clark RE,Holyoake TL,Wheadon H,Copland M

更新日期：2020-06-01 00:00:00

abstract：:Population-based studies of classical Hodgkin lymphoma (cHL) in contemporary clinical practice are scarce. The aim of this nationwide population-based study is to assess trends in primary therapy and relative survival (RS) during 1989-2017. We included 9,985 patients with cHL. Radiotherapy alone was virtually not appl...

journal_title：Leukemia

authors： Driessen J,Visser O,Zijlstra JM,Lugtenburg PJ,Plattel WJ,Kersten MJ,Dinmohamed AG

更新日期：2020-05-28 00:00:00

abstract：:T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological cancer characterized by skewed epigenetic patterns, raising the possibility of therapeutically targeting epigenetic factors in this disease. Here we report that among different cancer types, epigenetic factor TET1 is highly expressed in T-ALL a...

journal_title：Leukemia

authors： Bamezai S,Demir D,Pulikkottil AJ,Ciccarone F,Fischbein E,Sinha A,Borga C,Te Kronnie G,Meyer LH,Mohr F,Götze M,Caiafa P,Debatin KM,Döhner K,Döhner H,González-Menéndez I,Quintanilla-Fend L,Herold T,Jeremias I,Feuring-

更新日期：2020-05-15 00:00:00

abstract：:Transcriptional regulation of the HOXA genes is thought to involve CTCF-mediated chromatin loops and the opposing actions of the COMPASS and Polycomb epigenetic complexes. We investigated the role of these mechanisms at the HOXA cluster in AML cells with the common NPM1c mutation, which express both HOXA and HOXB gene...

journal_title：Leukemia

authors： Ghasemi R,Struthers H,Wilson ER,Spencer DH

更新日期：2020-05-12 00:00:00

abstract：:Acute graft-versus-host disease (aGVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (alloHCT) and is a major cause of morbidity and mortality. Systemic steroid therapy is the first-line treatment for aGVHD, although about half of patients will become refractory to treatment. As the n...

journal_title：Leukemia

authors： Malard F,Huang XJ,Sim JPY

更新日期：2020-05-01 00:00:00

abstract：:JAK2V617F is the most common mutation in patients with BCR-ABL negative myeloproliferative neoplasms (MPNs). The eradication of JAK2V617F hematopoietic stem cells (HSCs) is critical for achieving molecular remissions and cure. We investigate the distinct effects of two therapies, ruxolitinib (JAK1/2 inhibitor) and int...

journal_title：Leukemia

authors： Austin RJ,Straube J,Bruedigam C,Pali G,Jacquelin S,Vu T,Green J,Gräsel J,Lansink L,Cooper L,Lee SJ,Chen NT,Lee CW,Haque A,Heidel FH,D'Andrea R,Hill GR,Mullally A,Milsom MD,Bywater M,Lane SW

更新日期：2020-04-01 00:00:00

abstract：:We explored the association between bone marrow plasma cells (BMPCs) and disease presentation and outcome among 1574 AL patients. Three BMPC groups were formulated: <5% (n = 231, 15% of study population), 5-19% (n = 1045, 66%), and ≥20% (n = 298, 19%). Heart and renal involvement were more and less prevalent, respecti...

journal_title：Leukemia

authors： Muchtar E,Gertz MA,Kourelis TV,Sidana S,Go RS,Lacy MQ,Buadi FK,Dingli D,Hayman SR,Kapoor P,Leung N,Fonder A,Hobbs M,Lisa Hwa Y,Gonsalves W,Warsame R,Russell S,Lust JA,Lin Y,Zeldenrust S,Rajkumar SV,Kyle RA,Kum

更新日期：2020-04-01 00:00:00

abstract：:Despite considerable advances in the treatment of multiple myeloma (MM) in the last decade, a substantial proportion of patients do not respond to current therapies or have a short duration of response. Furthermore, these treatments can have notable morbidity and are not uniformly tolerated in all patients. As there i...

journal_title：Leukemia

authors： Shah N,Chari A,Scott E,Mezzi K,Usmani SZ

更新日期：2020-04-01 00:00:00

abstract：:Large granular lymphocyte leukemia (LGLL) is a rare and chronic lymphoproliferative disorder characterized by the clonal expansion of LGLs. LGLL patients can be asymptomatic or develop cytopenia, mostly neutropenia. Somatic STAT3 and STAT5b mutations have been recently reported in approximately 40% of patients. The ai...

journal_title：Leukemia

authors： Barilà G,Teramo A,Calabretto G,Vicenzetto C,Gasparini VR,Pavan L,Leoncin M,Vedovato S,Frigo AC,Facco M,Semenzato G,Zambello R

更新日期：2020-04-01 00:00:00

abstract：:Multiple myeloma (MM) is the second most common blood malignancy. Epidemiological family studies going back to the 1920s have provided evidence for familial aggregation, suggesting a subset of cases have an inherited genetic background. Recently, studies aimed at explaining this phenomenon have begun to provide direct...

journal_title：Leukemia

authors： Pertesi M,Went M,Hansson M,Hemminki K,Houlston RS,Nilsson B

更新日期：2020-03-01 00:00:00

abstract：:RAS-pathway mutations are recurrent events in myeloid malignancies. However, there is limited data on the significance of RAS-pathway mutations in patients with myelofibrosis (MF). We analyzed next-generation sequencing data of 16 genes, including RAS-pathway genes, from 723 patients with primary and secondary MF acro...

journal_title：Leukemia

authors： Santos FPS,Getta B,Masarova L,Famulare C,Schulman J,Datoguia TS,Puga RD,Alves Paiva RM,Arcila ME,Hamerschlak N,Kantarjian HM,Levine RL,Campregher PV,Rampal RK,Verstovsek S

更新日期：2020-03-01 00:00:00

abstract：:Multiple myeloma is the second most frequent hematological cancer after lymphoma and remains an incurable disease. The pervasive support provided by the bone marrow microenvironment to myeloma cells is crucial for their survival. Here, an unbiased assessment of receptor tyrosine kinases overexpressed in myeloma identi...

journal_title：Leukemia

authors： Frenquelli M,Caridi N,Antonini E,Storti F,Viganò V,Gaviraghi M,Occhionorelli M,Bianchessi S,Bongiovanni L,Spinelli A,Marcatti M,Belloni D,Ferrero E,Karki S,Brambilla P,Martinelli-Boneschi F,Colla S,Ponzoni M,DePinho R

更新日期：2020-01-01 00:00:00

abstract：:Allogeneic haemopoietic cell transplant (allo-HCT) may be curative in acute myeloid leukaemia (AML) in second complete remission (CR2) but the impact of reduced intensity (RIC) versus myeloablative conditioning (MAC) is uncertain. The Acute Leukaemia Working Party of the European Society for Blood and Bone Marrow Tran...

journal_title：Leukemia

authors： Gilleece MH,Labopin M,Savani BN,Yakoub-Agha I,Socié G,Gedde-Dahl T,Blaise D,Byrne JL,Craddock C,Cornelissen JJ,Arcese W,Forcade E,Crawley C,Polge E,Mohty M,Nagler A

更新日期：2020-01-01 00:00:00

abstract：:Mast cell leukemia (MCL) is a highly fatal malignancy characterized by devastating expansion of immature mast cells in various organs. Although considered a stem cell disease, little is known about MCL-propagating neoplastic stem cells. We here describe that leukemic stem cells (LSCs) in MCL reside within a CD34+/CD38...

journal_title：Leukemia

authors： Eisenwort G,Sadovnik I,Schwaab J,Jawhar M,Keller A,Stefanzl G,Berger D,Blatt K,Hoermann G,Bilban M,Willmann M,Winding C,Sperr WR,Arock M,Rülicke T,Reiter A,Valent P

更新日期：2019-11-01 00:00:00

abstract：:Older adults with acute myeloid leukemia (AML) who are not fit for standard chemotherapy historically have poor outcomes. Approximately 12-15% of older patients with AML harbor isocitrate dehydrogenase 2 (IDH2) gene mutations. Enasidenib is an oral inhibitor of mutant IDH2 proteins. Among 39 patients with newly diagno...

journal_title：Leukemia

authors： Pollyea DA,Tallman MS,de Botton S,Kantarjian HM,Collins R,Stein AS,Frattini MG,Xu Q,Tosolini A,See WL,MacBeth KJ,Agresta SV,Attar EC,DiNardo CD,Stein EM

更新日期：2019-11-01 00:00:00

abstract：:Abnormal karyotypes are common in cancer cells and frequently observed in acute myeloid leukemia (AML), in which complex karyotype aberrations are associated with poor prognosis. How exactly abnormal karyotypes arise and are propagated in AML is unclear. TP53 mutations and deletions are frequent in complex karyotype A...

journal_title：Leukemia

authors： Cazzola A,Schlegel C,Jansen I,Bochtler T,Jauch A,Krämer A

更新日期：2019-11-01 00:00:00